Cibus Inc. to Reveal First Quarter Financial Results
Cibus, Inc. (Nasdaq: CBUS), an innovative leader in agricultural biotechnology known for its groundbreaking gene editing technologies, is preparing to announce its first quarter financial results for 2025. Scheduled for Tuesday, the Cibus management team will host a conference call at 4:30 p.m. ET to provide detailed insights into the company's financial performance and the latest updates on their advancements.
Details of the Upcoming Conference Call
The conference call is set to deliver valuable information about Cibus' financial status and achievements. Participants can join by dialing the following numbers: +1-833-316-1983 for U.S. callers and +1-785-838-9310 internationally. To gain entry, callers will need the conference ID “CIBUS” or 24287. This session promises to be informative, allowing stakeholders to engage directly with Cibus' leadership.
Alternative Access to Conference Call Replays
For those unable to attend the live discussion, a replay of the conference call will be available until May 22, 2025. Dial in at +1-844-512-2921 within the U.S. and +1-412-317-6671 internationally, making sure to use the replay passcode: 11158792 to listen to the call.
Committed to Agricultural Innovation
Cibus stands at the forefront of agricultural innovation, focusing on gene-edited traits that offer significant solutions to the many challenges presented to farmers. The company aims to tackle productivity and sustainability issues, notably those caused by pests and diseases that the United Nations has identified as costing the global economy around $300 billion each year.
Understanding Cibus' Unique Approach
Rather than operating as a seed company, Cibus positions itself as a technology powerhouse. The firm utilizes advanced gene editing techniques to develop and license traits, partnering with seed companies to optimize agricultural output and subsequently benefiting from royalties on seed sales. This model allows Cibus to collaborate widely within the industry while maintaining its focus on innovation.
Pipeline of Productivity Traits
Currently, Cibus is working on an exciting pipeline that includes five distinct productivity traits. These traits are essential for addressing prevalent issues in crop production, focusing on needs like weed management in rice crops, pod shatter reduction, and resistance to Sclerotinia disease. By prioritizing these areas, Cibus aims to aid farmers in maximizing their yields and ensuring crop health.
Future of Agriculture with Cibus
Cibus' strategy is geared towards the major global row crops encompassing canola, corn, rice, soybean, and wheat. With its high-throughput gene editing technology, Cibus expects to drastically reduce the time and costs associated with conventional breeding methods. This technological advantage positions the company as a leader in advancing agricultural productivity sustainably, ensuring that farmers can remain competitive in a challenging market.
Contact Information for Inquiries
For investor inquiries, you can reach out to Karen Troeber at Cibus via email at ktroeber@cibus.com or call her at 858-450-2636. Additionally, for media relations, Colin Sanford is available at colin@bioscribe.com or 203-918-4347. For other inquiries, Jeff Sonnek can be contacted through jeff.sonnek@icrinc.com.
Frequently Asked Questions
What is the purpose of the conference call on May 8?
The conference call will focus on discussing Cibus' first quarter financial results and company updates.
How can I join the conference call?
You can dial in using the provided numbers for U.S. or international participants, along with the conference ID.
What If I miss the live call?
A replay of the conference will be available until May 22, 2025, using the specified dial-in numbers.
What technology does Cibus utilize in its innovations?
Cibus uses gene editing technologies to develop valuable traits for farming, which help address productivity and sustainability challenges.
Who can I contact for more information?
Contact Karen Troeber for investor relations or Colin Sanford for media inquiries via the provided email addresses.
